Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand

Ga Young Lee, Jong Ho Kim, Goo Taeg Oh, Byung Heon Lee, Ick Chan Kwon, In-San Kim

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Many cells, including macrophages, accumulate in atherosclerotic lesions, destabilizing plaques and driving plaque disruption. Therefore, macrophages serve as useful targets for atherosclerosis treatment and imaging. Stabilin-2 is a transmembrane protein expressed predominantly in macrophages and endothelial cells. In the present study, we found that stabilin-2 was widely expressed in atherosclerotic plaques than in normal vessel walls, and was present not only in macrophages but also in endothelial and smooth muscle cells in plaques. We used phage display technology to identify peptides that specifically bound to stabilin-2. After four rounds of selection, the most commonly isolated peptide had the sequence CRTLTVRKC, and was named S2P. We confirmed that this peptide specifically bound to stabilin-2-expressing cells in vitro and sinus endothelial cells in the spleen and lymph nodes in vivo. A FITC-conjugated synthetic CRTLTVRKC peptide was shown to home to atherosclerotic plaques in Ldlr-/- mice and to co-localize with endothelial cells, macrophages, and smooth muscle cells in such plaques. S2P conjugated to hydrophobically modified glycol chitosan nanoparticles was efficiently delivered to atherosclerotic plaques. These results show that the CRLTLTVRKC peptide homes to plaques by targeting stabilin-2; the peptide shows promise as a drug delivery moiety for, and an aid to molecular imaging of, atherosclerosis and other inflammatory diseases.

Original languageEnglish
Pages (from-to)211-217
Number of pages7
JournalJournal of Controlled Release
Volume155
Issue number2
DOIs
Publication statusPublished - 2011 Oct 30
Externally publishedYes

Fingerprint

Atherosclerotic Plaques
Ligands
Macrophages
Peptides
Endothelial Cells
Smooth Muscle Myocytes
Atherosclerosis
Molecular Imaging
Fluorescein-5-isothiocyanate
Bacteriophages
Nanoparticles
Spleen
Lymph Nodes
Technology
Pharmaceutical Preparations
Proteins

Keywords

  • Atherosclerosis
  • Nanoparticles
  • Phage display
  • Stabilin-2
  • Targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. / Lee, Ga Young; Kim, Jong Ho; Oh, Goo Taeg; Lee, Byung Heon; Kwon, Ick Chan; Kim, In-San.

In: Journal of Controlled Release, Vol. 155, No. 2, 30.10.2011, p. 211-217.

Research output: Contribution to journalArticle

Lee, Ga Young ; Kim, Jong Ho ; Oh, Goo Taeg ; Lee, Byung Heon ; Kwon, Ick Chan ; Kim, In-San. / Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. In: Journal of Controlled Release. 2011 ; Vol. 155, No. 2. pp. 211-217.
@article{16e780f62b5e4df68667f3ddf0a4d4cd,
title = "Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand",
abstract = "Many cells, including macrophages, accumulate in atherosclerotic lesions, destabilizing plaques and driving plaque disruption. Therefore, macrophages serve as useful targets for atherosclerosis treatment and imaging. Stabilin-2 is a transmembrane protein expressed predominantly in macrophages and endothelial cells. In the present study, we found that stabilin-2 was widely expressed in atherosclerotic plaques than in normal vessel walls, and was present not only in macrophages but also in endothelial and smooth muscle cells in plaques. We used phage display technology to identify peptides that specifically bound to stabilin-2. After four rounds of selection, the most commonly isolated peptide had the sequence CRTLTVRKC, and was named S2P. We confirmed that this peptide specifically bound to stabilin-2-expressing cells in vitro and sinus endothelial cells in the spleen and lymph nodes in vivo. A FITC-conjugated synthetic CRTLTVRKC peptide was shown to home to atherosclerotic plaques in Ldlr-/- mice and to co-localize with endothelial cells, macrophages, and smooth muscle cells in such plaques. S2P conjugated to hydrophobically modified glycol chitosan nanoparticles was efficiently delivered to atherosclerotic plaques. These results show that the CRLTLTVRKC peptide homes to plaques by targeting stabilin-2; the peptide shows promise as a drug delivery moiety for, and an aid to molecular imaging of, atherosclerosis and other inflammatory diseases.",
keywords = "Atherosclerosis, Nanoparticles, Phage display, Stabilin-2, Targeting",
author = "Lee, {Ga Young} and Kim, {Jong Ho} and Oh, {Goo Taeg} and Lee, {Byung Heon} and Kwon, {Ick Chan} and In-San Kim",
year = "2011",
month = "10",
day = "30",
doi = "10.1016/j.jconrel.2011.07.010",
language = "English",
volume = "155",
pages = "211--217",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand

AU - Lee, Ga Young

AU - Kim, Jong Ho

AU - Oh, Goo Taeg

AU - Lee, Byung Heon

AU - Kwon, Ick Chan

AU - Kim, In-San

PY - 2011/10/30

Y1 - 2011/10/30

N2 - Many cells, including macrophages, accumulate in atherosclerotic lesions, destabilizing plaques and driving plaque disruption. Therefore, macrophages serve as useful targets for atherosclerosis treatment and imaging. Stabilin-2 is a transmembrane protein expressed predominantly in macrophages and endothelial cells. In the present study, we found that stabilin-2 was widely expressed in atherosclerotic plaques than in normal vessel walls, and was present not only in macrophages but also in endothelial and smooth muscle cells in plaques. We used phage display technology to identify peptides that specifically bound to stabilin-2. After four rounds of selection, the most commonly isolated peptide had the sequence CRTLTVRKC, and was named S2P. We confirmed that this peptide specifically bound to stabilin-2-expressing cells in vitro and sinus endothelial cells in the spleen and lymph nodes in vivo. A FITC-conjugated synthetic CRTLTVRKC peptide was shown to home to atherosclerotic plaques in Ldlr-/- mice and to co-localize with endothelial cells, macrophages, and smooth muscle cells in such plaques. S2P conjugated to hydrophobically modified glycol chitosan nanoparticles was efficiently delivered to atherosclerotic plaques. These results show that the CRLTLTVRKC peptide homes to plaques by targeting stabilin-2; the peptide shows promise as a drug delivery moiety for, and an aid to molecular imaging of, atherosclerosis and other inflammatory diseases.

AB - Many cells, including macrophages, accumulate in atherosclerotic lesions, destabilizing plaques and driving plaque disruption. Therefore, macrophages serve as useful targets for atherosclerosis treatment and imaging. Stabilin-2 is a transmembrane protein expressed predominantly in macrophages and endothelial cells. In the present study, we found that stabilin-2 was widely expressed in atherosclerotic plaques than in normal vessel walls, and was present not only in macrophages but also in endothelial and smooth muscle cells in plaques. We used phage display technology to identify peptides that specifically bound to stabilin-2. After four rounds of selection, the most commonly isolated peptide had the sequence CRTLTVRKC, and was named S2P. We confirmed that this peptide specifically bound to stabilin-2-expressing cells in vitro and sinus endothelial cells in the spleen and lymph nodes in vivo. A FITC-conjugated synthetic CRTLTVRKC peptide was shown to home to atherosclerotic plaques in Ldlr-/- mice and to co-localize with endothelial cells, macrophages, and smooth muscle cells in such plaques. S2P conjugated to hydrophobically modified glycol chitosan nanoparticles was efficiently delivered to atherosclerotic plaques. These results show that the CRLTLTVRKC peptide homes to plaques by targeting stabilin-2; the peptide shows promise as a drug delivery moiety for, and an aid to molecular imaging of, atherosclerosis and other inflammatory diseases.

KW - Atherosclerosis

KW - Nanoparticles

KW - Phage display

KW - Stabilin-2

KW - Targeting

UR - http://www.scopus.com/inward/record.url?scp=80054090725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054090725&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2011.07.010

DO - 10.1016/j.jconrel.2011.07.010

M3 - Article

C2 - 21781994

AN - SCOPUS:80054090725

VL - 155

SP - 211

EP - 217

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -